Seegene Inc
Seegene, Inc. manufactures and sells molecular diagnostics products worldwide. It offers IVD products comprising respiratory disease detection products for respiratory infections; gastrointestinal disease detection products for gastrointestinal tract infections; human papillomavirus detection products; sexually transmitted infections causative pathogens detection products; tuberculosis detection … Read more
Seegene Inc (096530) - Total Liabilities
Latest total liabilities as of September 2025: ₩214.46 Billion KRW
Based on the latest financial reports, Seegene Inc (096530) has total liabilities worth ₩214.46 Billion KRW as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Seegene Inc - Total Liabilities Trend (2012–2024)
This chart illustrates how Seegene Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Seegene Inc Competitors by Total Liabilities
The table below lists competitors of Seegene Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Enaex S.A
SN:ENAEX
|
Chile | CL$1.00 Billion |
|
Bright Minds Biosciences Inc
NASDAQ:DRUG
|
USA | $1.60 Million |
|
Rogers Sugar Inc
PINK:RSGUF
|
USA | $668.39 Million |
|
Shen Ma Industry Co Ltd
SHG:600810
|
China | CN¥19.66 Billion |
|
Guangdong Haomei New Material Co Lt
SHE:002988
|
China | CN¥3.98 Billion |
|
Zhejiang Unifull Industrial Fibre Co Ltd
SHE:002427
|
China | CN¥1.52 Billion |
|
Drägerwerk AG & Co. KGaA
PINK:DGWPF
|
USA | $1.52 Billion |
|
Hanwang Technology Co Ltd
SHE:002362
|
China | CN¥729.61 Million |
Liability Composition Analysis (2012–2024)
This chart breaks down Seegene Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.83 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.18 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Seegene Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Seegene Inc (2012–2024)
The table below shows the annual total liabilities of Seegene Inc from 2012 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩223.80 Billion | +1.24% |
| 2023-12-31 | ₩221.05 Billion | -9.03% |
| 2022-12-31 | ₩243.01 Billion | -40.49% |
| 2021-12-31 | ₩408.31 Billion | -9.11% |
| 2020-12-31 | ₩449.26 Billion | +940.74% |
| 2019-12-31 | ₩43.17 Billion | +20.65% |
| 2018-12-31 | ₩35.78 Billion | -10.10% |
| 2017-12-31 | ₩39.80 Billion | -39.37% |
| 2016-12-31 | ₩65.65 Billion | +11.35% |
| 2015-12-31 | ₩58.96 Billion | +35.17% |
| 2014-12-31 | ₩43.62 Billion | -2.19% |
| 2013-12-31 | ₩44.59 Billion | +7.00% |
| 2012-12-31 | ₩41.68 Billion | -- |